Q-omics provides the consensus-scored MRPL36 profile across patient tissues and cancer cell-line models. MRPL36 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPL36 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, MRPL36 RNA expression shows 17,884 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where MRPL36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL36 survival associations across molecular data types. MRPL36 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL36 RNA expression–survival associations across cancer types. High MRPL36 expression shows unfavorable associations in UVM, KIRP, LIHC, BRCA, KICH and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPL36 RNA expression.
This table summarizes MRPL36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MRPL36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL36 shows higher tumor expression in COAD, HNSC, LIHC, KIRC, LUSC and LUAD. The COAD box plot shows higher MRPL36 RNA expression in tumor versus normal tissue (log2 FC = +1.212, t-test p < 0.001).
This table shows molecular features associated with MRPL36 in patient tissues and cancer cell lines. In patient samples, MRPL36 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL36 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and CNS.
